Chief Business Officer
Nicholas has 30 years’ experience in the pharmaceutical/ biotech industry and for the past 16 years has led Business Development groups at, and been on the Executive Teams of, Antisoma, Clavis Pharma, Redx Pharma and most recently ReNeuron. Over this time Nicholas has led or been instrumental in a range of over 25 global deals (including in-and out-licensing, divestments, spin-outs, royalty buy-out and M&A) with Big Pharma and biotechs; the out-licensing and divestment deals generated over US$240m. He started his career in clinical development, mainly in oncology, with Ciba-Geigy, Eisai and Cephalon. Nicholas has a degree in Biology and post-graduate diplomas from the College of Law, London. Nicholas joined OxSonics as Chief Business Officer in August 2020.